391 results on '"Olanow, C W"'
Search Results
2. Clinical approaches to the development of a neuroprotective therapy for PD
3. Cortical Mapping of Pathological Tau Proteins in Several Neurodegenerative Disorders
4. Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action
5. Manganese-Induced Neurotoxicity
6. Intranigral Iron Infusion as a Model for Parkinson’s Disease
7. Intranigral iron infusion in rats: A progressive model for excess nigral iron levels in Parkinson’s disease?
8. MR imaging of putamenal iron predicts response to dopaminergic therapy in parkinsonian patients
9. Supplement to: A double-blind, delayed-start trial of rasagiline in Parkin-sonʼs disease.
10. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress
11. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD)
12. Safety and tolerability of rasagiline in early Parkinsonʼs disease (PD): focus on safety aspects of special interest from the ADAGIO study: P1108
13. Rasagiline in early Parkinsonʼs disease (PD): additional results from the ADAGIO study: P1107
14. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction
15. Rasagiline in early Parkinsonʼs disease (PD): results from the ADAGIO study: LBN103
16. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease
17. Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version: 18
18. Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities
19. A scientific rationale for protective therapy in Parkinson's disease
20. Double-blind, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Stable Parkinson Disease
21. Manganese-Induced Parkinsonism and Parkinson's Disease
22. Surgical therapy for Parkinsonʼs disease
23. Cortical Mapping of Pathological Tau Proteins in Several Neurodegenerative Disorders
24. Inflammatory Response and Oxidative Stress in the Degeneration of Dopamine Neurons in Parkinson's Disease
25. Fetal Nigral Transplantation as a Therapy for Parkinson's Disease
26. Fetal Nigral Transplantation as a Therapy for Parkinson’s Disease
27. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
28. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary
29. Inflammatory Response and Oxidate Stress in the Degeneration of Dopamine Neurons in Parkinson's Disease
30. The delayed-start study in Parkinson disease: Can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?
31. The delayed-start study in Parkinson disease: Can't satisfy everyone
32. Inflammatory Response and Oxidative Stress in the Degeneration of Dopamine Neurons in Parkinson's Disease
33. The scientific and clinical basis for the treatment of Parkinson disease (2009)
34. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease
35. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
36. DLB and PDD boundary issues
37. The pathogenesis of cell death in Parkinson's disease
38. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
39. Proteasomal dysfunction in sporadic Parkinson's disease
40. Occupation and parkinsonism in three movement disorders clinics
41. Melvin David Yahr, MD (1917-2004)
42. Continuous dopaminergic stimulation in early and advanced Parkinson's disease
43. COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?
44. Fetal Nigral Transplantation as a Therapy for Parkinson's Disease.
45. Why delaying levodopa is a good treatment strategy in early Parkinson's disease
46. Falling asleep at the wheel: Motor vehicle mishaps in people taking pramipexole and ropinirole
47. High Frequency Stimulation of the Subthalamic Nucleus as a Treatment for Parkinson's Disease: A 12 Month Follow-up Study
48. ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
49. Effect of selegiline on mortality in patients with Parkinson's disease
50. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.